Page 1

August 9 , 2021 IMMUNOVANT Immunovant Reports Financial Results for the Quarter Ended June 30 , 2021 Company Ended the Quarter With Cash of Approximately $ 379 Million and Subsequently Received a Direct Investment of $ 200 Million from Roivant NEW YORK , Aug. 09 , 2021 ( GLOBE NEWSWIRE ) -- Immunovant , Inc. ( Nasdaq : IMVT ) , a clinical - stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases , today reported financial results for its fiscal first quarter ended June 30 , 2021. Immunovant ended the quarter with approximately $ 379 million in cash . " We are excited to announce that in July 2021 , the FDA granted Orphan Drug Designation to IMVT - 1401 for treatment of Myasthenia Gravis , " said Pete Salzmann , M.D. , Chief Executive Officer of Immunovant . " We have also initiated engagement with the FDA's Division of Neurology to discuss protocol modifications for a pivotal study in Myasthenia Gravis and our team is excited to reach alignment with the FDA prior to the end of the year " continued Dr. Salzmann . Immunovant plans to initiate a pivotal study in Myasthenia Gravis ( " MG " ) in early 2022 . Immunovant also plans to resume development in Warm Autoimmune Hemolytic Anemia ( " WAIHA " ) and in Thyroid Eye Disease ( “ TED ” ) and initiate clinical studies in at least two other indications in the next 12 months . Immunovant expects at least one of these indications ( beyond MG ) to be a pivotal study . On August 2nd , Immunovant announced that it had received a $ 200 million strategic investment from Roivant Sciences . Immunovant intends to use the proceeds from this investment to expedite development of IMVT - 1401 in multiple indications . Immunovant will host a conference call and audio webcast on Monday , August 9 , 2021 at 8 a.m. ET . Following prepared remarks , the call will include a live question - and - answer session for the investment community . To access the webcast , please visit Immunovant's website at www.immunovant.com . Participants may also dial in using the numbers provided below : Toll Free : 1-877-407-9039 Toll / International : 1-201-689-8470 An archived webcast recording will be available on Immunovant's website for a limited time . Financial Highlights for Fiscal First Quarter Ended June 30 , 2021 : R & D Expenses : Research and development expenses were $ 18.7 million for the three months ended June 30 , 2021 , compared to $ 16.9 million for the three months ended June